Quick Answer
Gossamer Bio, Inc. reported Long-Term Debt of $0.00 for fiscal year 2024.
Gossamer Bio, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2024 | $0.00 | -100.0% |
| 2023 | $814.0K | -93.2% |
| 2022 | $11.99M | -58.8% |
| 2021 | $29.08M | +1.2% |
| 2020 | $28.74M | +1.0% |
| 2019 | $28.46M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $0.00 | -100.0% | — |
| June 30, 2024 | $0.00 | -100.0% | — |
| March 31, 2024 | $0.00 | -100.0% | -100.0% |
| December 31, 2023 | $814.0K | -93.2% | -77.6% |
| September 30, 2023 | $3.63M | -75.5% | -43.5% |
| June 30, 2023 | $6.44M | -63.5% | -30.2% |
| March 31, 2023 | $9.22M | -68.4% | -23.1% |
| December 31, 2022 | $11.99M | -58.8% | -19.2% |
- Gossamer Bio, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2019–2024 period, Gossamer Bio, Inc.’s long-term debt has declined by 100.0% (from $28.46 million to $0.00).
- The most recent figure is from Gossamer Bio, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 13, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: